I didn't get to listen real-time, so just listened to replay. I felt way better after hearing what she had to say. I definitely wanted a little better transparency on profitability leading up to call. Those DIR fees are tricky though. I work in pharmacy and you literally have no clue what they are going to bill you for, just discussed those this week even. Hence much needed legislation.
Jimmy Quick, an S-1 for a company already publicly trading does not uplist a company;
An S-1 is a registration of new stock. Is RXMD going to do an exchange of current shares for newly created shares priced higher to meet Nasdaq basic requirements? Less than 10 cents a share will not get them there.